Data from: INTREPAD: a randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease

Pierre-Francois Meyer, Jennifer Tremblay-Mercier, Jeannie Leoutsakos, Cecile Madjar, Marie-Elyse Lafaille-Magnan, Melissa Savard, Pedro Rosa-Neto, Judes Poirier, Pierre Etienne & John Breitner
Objective: Evaluate the safety and efficacy of low-dose naproxen for prevention of progression in pre-symptomatic AD among cognitively intact persons at-risk. Methods: INTREPAD, a two-year double-masked pharmaco-prevention trial, enrolled 195 AD family history-positive elderly (mean age 63 years) screened carefully to exclude cognitive disorder. These were randomized 1:1 to naproxen sodium 220mg twice-daily or placebo. Multimodal imaging, neurosensory, cognitive and (in ~50%) CSF biomarker evaluations were performed at Baseline, 3, 12, and 24 months. A...
1 citation reported since publication in 2019.
193 views reported since publication in 2019.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?
44 downloads reported since publication in 2019.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?